A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultane

Grants and Contracts Details

StatusActive
Effective start/end date7/12/23 → 7/12/25

Funding

  • PPD Investigator Services LLC: $42,196.00